Stroke and Mechanical Circulatory Support in Adults.
David J BaeJoshua Zebadiah WilleyChinwe IbehMelana YuzefpolskayaPaolo C ColomboPublished in: Current cardiology reports (2023)
Short-term devices such as intra-aortic balloon pump, Impella, TandemHeart, and Venoatrial Extracorporal Membrane Oxygenation, as well as durable continuous-flow left ventricular assist devices (LVADs), improve cardiac output and blood flow to the vital organs. However, MCS use is associated with high rates of complications, including ischemic and hemorrhagic strokes which carry a high risk for death and disability. Improvements in MCS technology have reduced but not eliminated the risk of stroke. Mitigation strategies focus on careful management of anti-thrombotic therapies. While data on therapeutic options for stroke are limited, several case series reported favorable outcomes with thrombectomy for ischemic stroke patients with large vessel occlusions, as well as with reversal of anticoagulation for those with hemorrhagic stroke. Stroke in patients treated with MCS is associated with high morbidity and mortality. Preventive strategies are targeted based on the specific form of MCS. Improvements in the design of the newest generation device have reduced the risk of ischemic stroke, though hemorrhagic stroke remains a serious complication.
Keyphrases
- atrial fibrillation
- left ventricular
- blood flow
- left atrial
- heart failure
- cerebral ischemia
- type diabetes
- catheter ablation
- multiple sclerosis
- acute coronary syndrome
- percutaneous coronary intervention
- metabolic syndrome
- climate change
- extracorporeal membrane oxygenation
- skeletal muscle
- drug delivery
- coronary artery disease
- coronary artery
- pulmonary artery
- weight loss
- risk factors
- transcatheter aortic valve replacement
- acute ischemic stroke